世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000031810

肝臓癌治療薬の世界市場(2022-2026)

TechNavio

Global Liver Cancer Drugs Market 2022-2026

発刊日 2022/03/23

言語英語

体裁PDF/120ページ

ライセンス/価格120ページ

0000031810

Single
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

本レポートは、肝臓癌治療薬市場を分析します。

世界の肝臓癌治療薬市場は、予測期間中に約14.67 %のCAGRで推移し、2022年から2026年の間に52億9,000万USドルの成長が見込まれています。本レポートは、総体的な分析、市場規模と予測、動向、成長推進要因、課題、および約25社のベンダーを対象とするベンダー分析を提供しています。

本レポートは、現在の世界市場シナリオ、最新動向と成長推進要因、および全体的な市場環境に関する最新の分析を提供します。この市場は、肝臓癌罹患率の増加、診断方法の進歩、有利な償還シナリオによって牽引されています。

調査範囲

  • 市場セグメント
    ➣ タイプ別
      ◇ 免疫療法
      ◇ 標的療法
    ➣ 地域別
      ◇ 北アメリカ
      ◇ ヨーロッパ
      ◇ アジア
      ◇ その他の地域

本調査では、今後数年間の肝臓癌治療薬市場の成長を促進する主要な理由の一つとして、mABの使用を挙げています。また、肝臓癌における精密癌医療の導入や肝臓癌治療薬開発のための共同研究の増加が、市場の大きな需要につながると考えられます。

TechNavio社は、主要なパラメーターの分析による複数のソースからのデータの調査、合成、および合計によって、市場の詳細な状況を提示します。

本レポートは以下の分野をカバーしています。

  • 肝臓癌治療薬の市場規模
  • 肝臓癌治療薬の市場予測
  • 肝臓癌治療薬市場の業界分析

TechNavio社の堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されており、これに沿って、主要な肝臓癌治療薬市場ベンダーの詳細な分析を提供します

  • 調査企業
    ➣ Alnylam Pharmaceuticals Inc.
    ➣ AstraZeneca Plc
    ➣ Bayer AG
    ➣ Bristol-Myers Squibb Co.
    ➣ エーザイ(Eisai Co. Ltd.)
    ➣ Eli Lilly and Co.
    ➣ Eureka Therapeutics
    ➣ Exelixis Inc.
    ➣ F. Hoffmann La Roche Ltd.
    ➣ Gilead Sciences Inc.
    ➣ Jiangsu Hengrui Pharmaceuticals Co. Ltd.
    ➣ Lion TCR Pte. Ltd.
    ➣ Merck and Co. Inc.
    ➣ Novartis AG
    ➣ 小野薬品工業(Ono Pharmaceutical Co. Ltd.)
    ➣ Pfizer Inc.
    ➣ Q BioMed Inc.

また、本レポートには、市場の成長に影響を与える今後の動向と課題に関する情報が含まれており、企業が今後のすべての成長機会を戦略化し、活用するのに役立ちます。

この調査は、業界の主要な参加者からの情報を含む、一次情報と二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加えて、包括的な市場とベンダー情勢が含まれています。

TechNavio社について

TechNavio社は、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析により、複数のソースからのデータの調査、統合、および集計により、市場の詳細な状況を提示します。また、業界の主要なインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは、包括的で信頼性が高く、一次および二次の広範な調査の結果です。TechNavio社の市場調査レポートは、完全な競争環境と、質的および量的調査を使用して正確な市場成長を予測する詳細なベンダー選択の調査手法と分析を提供します。

レポート詳細

目次

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type
5.1 Market segments
Exhibit 24: Chart on Type - Market share 2021-2026 (%)
Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 26: Chart on Comparison by Type
Exhibit 27: Data Table on Comparison by Type
5.3 Immunotherapy - Market size and forecast 2021-2026
Exhibit 28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)
5.4 Targeted therapy - Market size and forecast 2021-2026
Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Type
Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape
6.1 Customer landscape overview
Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 China - Market size and forecast 2021-2026
Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
7.10 Canada - Market size and forecast 2021-2026
Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.11 UK - Market size and forecast 2021-2026
Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 79: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 81: Overview on factors of disruption
9.4 Industry risks
Exhibit 82: Impact of key risks on business

10 Vendor Analysis
10.1 Vendors covered
Exhibit 83: Vendors covered
10.2 Market positioning of vendors
Exhibit 84: Matrix on vendor position and classification
10.3 AstraZeneca Plc
Exhibit 85: AstraZeneca Plc - Overview
Exhibit 86: AstraZeneca Plc - Product / Service
Exhibit 87: AstraZeneca Plc - Key news
Exhibit 88: AstraZeneca Plc - Key offerings
10.4 Bayer AG
Exhibit 89: Bayer AG - Overview
Exhibit 90: Bayer AG - Business segments
Exhibit 91: Bayer AG - Key news
Exhibit 92: Bayer AG - Key offerings
Exhibit 93: Bayer AG - Segment focus
10.5 Bristol-Myers Squibb Co.
Exhibit 94: Bristol-Myers Squibb Co. - Overview
Exhibit 95: Bristol-Myers Squibb Co. - Product / Service
Exhibit 96: Bristol-Myers Squibb Co. - Key offerings
10.6 Eisai Co. Ltd.
Exhibit 97: Eisai Co. Ltd. - Overview
Exhibit 98: Eisai Co. Ltd. - Business segments
Exhibit 99: Eisai Co. Ltd. - Key offerings
Exhibit 100: Eisai Co. Ltd. - Segment focus
10.7 Eli Lilly and Co.
Exhibit 101: Eli Lilly and Co. - Overview
Exhibit 102: Eli Lilly and Co. - Business segments
Exhibit 103: Eli Lilly and Co. - Key offerings
Exhibit 104: Eli Lilly and Co. - Segment focus
10.8 Eureka Therapeutics
Exhibit 105: Eureka Therapeutics - Overview
Exhibit 106: Eureka Therapeutics - Product / Service
Exhibit 107: Eureka Therapeutics - Key offerings
10.9 Gilead Sciences Inc.
Exhibit 108: Gilead Sciences Inc. - Overview
Exhibit 109: Gilead Sciences Inc. - Business segments
Exhibit 110: Gilead Sciences Inc. - Key news
Exhibit 111: Gilead Sciences Inc. - Key offerings
Exhibit 112: Gilead Sciences Inc. - Segment focus
10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
10.11 Lion TCR Pte. Ltd
Exhibit 116: Lion TCR Pte. Ltd - Overview
Exhibit 117: Lion TCR Pte. Ltd - Product / Service
Exhibit 118: Lion TCR Pte. Ltd - Key offerings
10.12 Merck and Co. Inc.
Exhibit 119: Merck and Co. Inc. - Overview
Exhibit 120: Merck and Co. Inc. - Business segments
Exhibit 121: Merck and Co. Inc. - Key news
Exhibit 122: Merck and Co. Inc. - Key offerings
Exhibit 123: Merck and Co. Inc. - Segment focus

11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 124: Inclusions checklist
Exhibit 125: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 126: Currency conversion rates for US$
11.4 Research methodology
Exhibit 127: Research methodology
Exhibit 128: Validation techniques employed for market sizing
Exhibit 129: Information sources
11.5 List of abbreviations
Exhibit 130: List of abbreviations
The market is led by the UK, Germany, and France. The market will experience moderate growth during the forecast period. One of the major factors is the increase in the prevalence of liver cancer in the region. Liver cancer can be caused due to various infectious diseases such as chronic hepatitis B infection and hepatitis C virus infections. Liver cancer is the 18th most common cancer in the UK. In Europe, 28% of the cases of liver cancer are due to chronic hepatitis B infection, and 21% of the cases are due to hepatitis C virus infections.

Exhibits
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Incremental Growth
Exhibits7: Executive Summary - Data Table on Incremental Growth
Exhibits8: Executive Summary - Chart on Vendor Market Positioning
Exhibits9: Parent market
Exhibits10: Market Characteristics
Exhibits11: Offerings of vendors included in the market definition
Exhibits12: Market segments
Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits17: Five forces analysis - Comparison between 2021 and 2026
Exhibits18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits23: Chart on Market condition - Five forces 2021 and 2026
Exhibits24: Chart on Type - Market share 2021-2026 (%)
Exhibits25: Data Table on Type - Market share 2021-2026 (%)
Exhibits26: Chart on Comparison by Type
Exhibits27: Data Table on Comparison by Type
Exhibits28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
Exhibits31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)
Exhibits32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibits33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibits34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibits35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibits36: Market opportunity by Type ($ million)
Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits40: Chart on Geographic comparison
Exhibits41: Data Table on Geographic comparison
Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits61: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits66: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits67: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits68: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits69: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits77: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits78: Market opportunity By Geographical Landscape ($ million)
Exhibits79: Impact of drivers and challenges in 2021 and 2026
Exhibits80: Overview on Criticality of inputs and Factors of differentiation
Exhibits81: Overview on factors of disruption
Exhibits82: Impact of key risks on business
Exhibits83: Vendors covered
Exhibits84: Matrix on vendor position and classification
Exhibits85: AstraZeneca Plc - Overview
Exhibits86: AstraZeneca Plc - Product / Service
Exhibits87: AstraZeneca Plc - Key news
Exhibits88: AstraZeneca Plc - Key offerings
Exhibits89: Bayer AG - Overview
Exhibits90: Bayer AG - Business segments
Exhibits91: Bayer AG - Key news
Exhibits92: Bayer AG - Key offerings
Exhibits93: Bayer AG - Segment focus
Exhibits94: Bristol-Myers Squibb Co. - Overview
Exhibits95: Bristol-Myers Squibb Co. - Product / Service
Exhibits96: Bristol-Myers Squibb Co. - Key offerings
Exhibits97: Eisai Co. Ltd. - Overview
Exhibits98: Eisai Co. Ltd. - Business segments
Exhibits99: Eisai Co. Ltd. - Key offerings
Exhibits100: Eisai Co. Ltd. - Segment focus
Exhibits101: Eli Lilly and Co. - Overview
Exhibits102: Eli Lilly and Co. - Business segments
Exhibits103: Eli Lilly and Co. - Key offerings
Exhibits104: Eli Lilly and Co. - Segment focus
Exhibits105: Eureka Therapeutics - Overview
Exhibits106: Eureka Therapeutics - Product / Service
Exhibits107: Eureka Therapeutics - Key offerings
Exhibits108: Gilead Sciences Inc. - Overview
Exhibits109: Gilead Sciences Inc. - Business segments
Exhibits110: Gilead Sciences Inc. - Key news
Exhibits111: Gilead Sciences Inc. - Key offerings
Exhibits112: Gilead Sciences Inc. - Segment focus
Exhibits113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibits114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibits115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
Exhibits116: Lion TCR Pte. Ltd - Overview
Exhibits117: Lion TCR Pte. Ltd - Product / Service
Exhibits118: Lion TCR Pte. Ltd - Key offerings
Exhibits119: Merck and Co. Inc. - Overview
Exhibits120: Merck and Co. Inc. - Business segments
Exhibits121: Merck and Co. Inc. - Key news
Exhibits122: Merck and Co. Inc. - Key offerings
Exhibits123: Merck and Co. Inc. - Segment focus
Exhibits124: Inclusions checklist
Exhibits125: Exclusions checklist
Exhibits126: Currency conversion rates for US$
Exhibits127: Research methodology
Exhibits128: Validation techniques employed for market sizing
Exhibits129: Information sources
Exhibits130: List of abbreviations

この商品のレポートナンバー

0000031810

TOP